Sarepta Therapeutics Newsroom

BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200

Futu NewsJan 28 21:31 · Ratings

A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $195 to $217

Futu NewsJan 28 21:00 · Ratings

Sarepta Therapeutics' Strong Market Position and Elevidys' Promising Prospects Drive Buy Rating

TipRanksJan 28 20:25 · Ratings

Analysts' Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT) and Roche Holding AG (OtherRHHVF)

TipRanksJan 28 05:50 · Ratings

Sarepta Therapeutics Price Target Maintained With a $202.00/Share by Needham

Dow JonesJan 28 02:45 · Ratings

Buy Rating Reaffirmed for Sarepta Therapeutics Following Positive EMBARK Study Results

TipRanksJan 28 02:05 · Ratings

Sarepta Therapeutics Says Phase 3 Study of Potential Muscular Dystrophy Drug Shows 'Positive' Results

MT NewswiresJan 27 17:28

Sarepta's EMBARK Study Part 2 Results: ELEVIDYS Gene Therapy Shows Sustained Functional Gains And Disease Stabilization In Duchenne Muscular Dystrophy

BenzingaJan 27 14:30

Express News | Sarepta Therapeutics Announces Results From Part 2 of the Embark Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals With Duchenne Muscular Dystrophy Following Treatment With Elevidys

BreakingsJan 27 14:00

Sarepta Therapeutics Announces Results From Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals With Duchenne Muscular Dystrophy Following Treatment With ELEVIDYS

BusinesswireJan 27 14:00

RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $165

Futu NewsJan 23 10:31 · Ratings

RBC Capital Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

TipRanksJan 23 09:58 · Ratings

TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203

Futu NewsJan 21 23:31 · Ratings

TD Cowen Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

TipRanksJan 21 23:15 · Ratings

Express News | Sarepta Therapeutics Inc : Leerink Partners Cuts Target Price to $200 From $210

BreakingsJan 20 23:53

A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $75 to $203

Futu NewsJan 15 21:00 · Ratings

Sarepta Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Dow JonesJan 15 20:18 · Ratings

Temporary Revenue Surge and Market Penetration Concerns Lead to Sell Rating for Sarepta Therapeutics

TipRanksJan 15 19:26 · Ratings

Sarepta, Biogen Drugs With Accelerated Approval Under Fire in FDA Report

Seeking AlphaJan 15 05:57

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target

BenzingaJan 14 21:14 · Ratings